TIGIT and neoplasm: Interestingly, a complete response (CR) of the primary CT26 tumor was observed in 2 of 8 (25%) mice given OAd-null treatment and in 4 of 8 (50%) mice given OAd-TIGIT-Fc treatment (Supplementary Fig. 13a, b).